1. Pfizer may seek US green light to use COVID vaccine in late Nov  Al Jazeera English
  2. Pfizer says it will not have a coronavirus vaccine until late November, allaying fears of a rush for approval before Election Day  The Washington Post
  3. Pfizer says earliest US filing for COVID-19 vaccine would be late November  Reuters
  4. China's Covid-19 vax is safe, prompts antibody response..  Greatandhra.com
  5. Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners.  Barron's
  6. View Full coverage on Google News
But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.But that makes it unlikely a vaccine will be available before the US election which President Trump has promised.

search

Pfizer Inc. said it could seek emergency-use authorization for its COVID-19 vaccine in the U.S. by late November if the shot is shown to be effective in a large late-stage trial.

Pfizer confirms possible November COVID vaccine application - BNN Bloomberg

Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that's if everything goes well, the company's CEO announced Friday.Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that's if everything goes well, the company's CEO announced Friday.

Pfizer: Mid-November earliest it can seek coronavirus vaccine OK | CTV News

Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.

Coronavirus vaccine: Pfizer may ask for emergency approval in late November - National | Globalnews.ca

An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.

Pfizer CEO letter makes Thanksgiving earliest date for COVID-19 vaccine

There won’t be a coronavirus vaccine ready before Election Day, despite President Donald Trump’s repeated promises and vaccine makers’ breakneck speed.

Pfizer delivers final blow to Trump's hope for preelection vaccine - POLITICO

Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.

Outbreaks in the Midwest driving surge in COVID-19 cases

Pfizer (PFE) stock is on the higher after the company announced it could submit an Emergency Use Authorization application by as soon as the end of November

Blue-Chip Drugmaker Moves Higher on Vaccine Announcement

Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...Moderna stock has rallied by almost 15% over the past month, as the company continues with its phase 3 clinical trials, with late-stage clinical data likely available in the next month or so. Moderna says that it could file for emergency use authorization from the U.S. FDA around November 25...

What’s Happening With Moderna Stock?

Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day. Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day.

Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners. | Barron's

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Chinese COVID-19 vaccine candidate shows promise in human trial: Study | Health

The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available ...The mRNA coronavirus vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is unlikely to become available under emergency use...

Pfizer, Inc. (NYSE:PFE), (BNTX) - Pfizer CEO: Emergency Use Application For Coronavirus Vaccine Could Come In Late November | Benzinga

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.The CDC put out a central playbook for how to distribute the shots. But how states will address these guidelines is anything but uniform.

In the US, 50 States Could Mean 50 Vaccine Rollout Strategies | WIRED

A $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said Thursday residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine thatA $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet

$60 experimental coronavirus vaccine rolled out in eastern Chinese city | Deccan Herald

WASHINGTON, Oct 17 — Two American companies expect to apply for emergency approval for their Covid-19 vaccines by late November, welcome news as the US crossed eight million confirmed cases amid a third surge of its coronavirus epidemic. Pfizer said yesterday it hopes to move ahead with its...WASHINGTON, Oct 17 — Two American companies expect to apply for emergency approval for their Covid-19 vaccines by late November, welcome news as the US crossed eight million confirmed cases amid a third surge of its coronavirus epidemic. Pfizer said yesterday it hopes to move ahead with its...

US hoping for two Covid-19 vaccines by end of November | World | Malay Mail

India News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk populIndia News: As the world prepares for a vaccine against Covid-19, India has started identifying around 30 crore priority beneficiaries, including high-risk popul

Covid-19: Govt identifying 30 crore who will get vaccine on priority | India News - Times of India

Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.Pfizer CEO Albert Bourla recently suggested the company would know whether its BioNTech-shared COVID-19 vaccine works by October. Criticism ensued. Now finding himself alone in the biopharma world with that bullish estimate, the Big Pharma chief is changing his tone.

Pfizer CEO, facing pushback, shifts COVID-19 vaccine timeline to late November | FiercePharma

Pfizer has announced plans to submit an application to the US FDA seeking approval for its Covid-19 vaccine candidate next month.Pfizer has announced plans to submit an application to the US FDA seeking approval for its Covid-19 vaccine candidate next month.

Pfizer to seek approval for Covid-19 vaccine candidate next month

COVID-19 vaccine, and China-Africa health cooperation, are their focus.

50 African diplomats visit Chinese coronavirus vaccine maker - CGTN

Covid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing tooCovid-19 vaccine trials are advancing fast – but anti-vaccine sentiment is growing too

‘Stick your vaccine up your arse’ – the Covid-19 vaccine, the science and the sceptics

US pharmaceutical giant Pfizer says it will likely apply for emergency authorization of a coronavirus vaccine in the United States as early as late November.US pharmaceutical giant Pfizer says it will likely apply for emergency authorization of a coronavirus vaccine in the United States as early as late November.

Pfizer may seek vaccine approval in late Nov. | NHK WORLD-JAPAN News

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.The drug maker’s CEO said Pfizer plans to apply for emergency use authorization by late November.

Pfizer won't be seeking emergency approval for coronavirus vaccine before election | TheHill

Pharmaceutical giant Pfizer has put the kibosh on any dreams of rushing out its experimental covid-19 vaccine before the U.S. election day. The good news is that the company is optimistic that its vaccine will be ready to apply for the Food and Drug Administration’s emergency use authorization (EUA) by the end of November, raising hopes that it could see use in the U.S. before the end of 2020.Pharmaceutical giant Pfizer has put the kibosh on any dreams of rushing out its experimental covid-19 vaccine before the U.S. election day. The good news is that the company is optimistic that its vaccine will be ready to apply for the Food and Drug Administration’s emergency use authorization (EUA) by the end of November, raising hopes that it could see use in the U.S. before the end of 2020.

Pfizer Says Vaccine Could Be Ready for Review by Late November

Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.

Sanofi and its partner Translate Bio tested their mRNA COVID-19 vaccine candidate MRT5500 in mice and macaques and found that the animals developed neutralizing antibodies and a favorable T-cell response, they reported. A phase 1/2 trial is expected to start this quarter.Sanofi and its partner Translate Bio tested their mRNA COVID-19 vaccine candidate MRT5500 in mice and macaques and found that the animals developed neutralizing antibodies and a favorable T-cell response, they reported. A phase 1/2 trial is expected to start this quarter.

COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study | FierceBiotech

The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.The head of the UK Vaccine Taskforce says it would not mean that life would get back to normal straight away.

sign-in

NEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-NovemberNEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November

Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November | Euronews

According to the recent World Bank report, an estimated 1 billion students in developing nations may be out of school. CoronavirusA World Bank report says about 1 billion students in developing countries may be out of school due to the looming second wave of COVID-19.

1 billion students in developing nations may be out of school due to second wave of COVID-19 - World Bank | Nairametrics

A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.

Pfizer could seek November vaccine authorization | WWMT

Pfizer could seek November vaccine authorization

Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.

US surpasses 8 million COVID-19 cases | CIDRAP

The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.

Pfizer Hopes to Apply for Coronavirus Vaccine Emegency Use Authorization in November | The Motley Fool

US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…

Pfizer plans to seek authorization for Covid-19 vaccine next month

Investors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals companyInvestors have been closely following every twist and turn in the global race to develop a coronavirus vaccine. Yesterday it was Pfizer’s turn in the spotlight.The American pharmaceuticals company

Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.

The race for a COVID-19 vaccine heats up

On Friday, Pfizer announced that it may attempt to file for emergency use authorization with the FDA by late November. This comes as the WHO says Remdesivir has ‘little or no effect’ in preventing deaths in patients with coronavirus. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.On Friday, Pfizer announced that it may attempt to file for emergency use authorization with the FDA by late November. This comes as the WHO says Remdesivir has ‘little or no effect’ in preventing deaths in patients with coronavirus. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

Coronavirus Latest: Friday, October 16

The documents were submitted to the Center of Disease Control and Prevention for review and approval.The documents were submitted to the Center of Disease Control and Prevention for review and approval.

Iowa health officials submit plan to CDC on distributing vaccine when available

WASHINGTON" The US pharmaceutical giant Pfizer expects to file for emergency use authorisation for its Covid-19 vaccine in late November, around two weeks after the Nov 3 US presidential election, it said on Friday.WASHINGTON" The US pharmaceutical giant Pfizer expects to file for emergency use authorisation for its Covid-19 vaccine in late November, around two weeks after the Nov 3 US presidential election, it said on Friday.

Pfizer to seek vaccine approval in November

LAS VEGAS (FOX5) -- Nevada's Department of Health and Human Services, Division of Public and Behavioral Health submitted a vaccine program to the Centers for Disease Control and Prevention.LAS VEGAS (FOX5) -- Nevada's Department of Health and Human Services, Division of Public and Behavioral Health submitted a vaccine program to the Centers for Disease Control and Prevention.

Nevada submits COVID-19 vaccine program to CDC | Coronavirus | fox5vegas.com

The move is aimed at boosting public confidence in homegrown inoculations, the WSJ reported, citing a company website and some students who applied for it.

China's Sinopharm Offers Experimental COVID-19 Vaccines to Students - The Wire Science

Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.

Pfizer COVID-19 Vaccine Delayed Until At Least Late November : Coronavirus Live Updates : NPR